Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
leggi di più
leggi meno
10 anni fa
#asco, #cancer, #cancergrace, #checkpoint, #david, #dr, #edward, #garon, #geffen, #grace, #gracecast, #highlights, #immune, #inhibitor, #lung, #medicine, #of, #school, #spigel, #ucla
